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The FabH enzyme fromM. tuberculosis binds the acyl tail of large substrates at the end of a buried hydropho-
bic tunnel. Sachdeva et al. (2008) use reactive chemical probes and X-ray crystallography to show that
substrates can bind to an open state of FabH without threading through the tunnel.Mycobacterium tuberculosis, a deadly hu-
man pathogen, is protected by a thick,
waxy cell wall containing long-chain fatty
acids. These fatty acids, called mycolic
acids, are typically over 60 carbons in
length and are known to be important for
the growth, survival, and pathogenicity of
M. tuberculosis. Mycolic acids confer
unique physical features to Mycobacteria,
such as low membrane permeability, that
contribute to antibiotic resistance, as
well as the ability to survive inside macro-
phages and evade immune surveillance.
These properties result in persistent,
long-term infections in humans and are re-
sponsible for the emergence of tuberculo-
sis as one of the most widespread and
deadly infectious diseases worldwide.
Not surprisingly, the biosynthesis of
mycolic acids has been the focus of anti-
tubercular drug discovery efforts. Two
front-line drugs, isoniazid and ethion-
amide, inhibit fatty acid biosynthesis
enzymes required for the production of
mycolic acids. Other M. tuberculosis fatty
acid biosynthesis enzymes could prove to
be equally good drug targets. In this issue
ofChemistry & Biology, Sachdeva and co-
workers focus on FabH, another enzyme
of fatty acid biosynthesis that has not yet
been exploited as a tuberculosis drug
target (Sachdeva et al., 2008). In this work,
reactive chemical probes are cleverly
employed to demonstrate that substrates
can bind to an open state of M. tuberculo-
sis FabH, bypassing a route previously
thought to provide the only access to the
active site.
Bacterial FabH enzymes typically ac-
cept acyl-CoenzymeA (CoA) substrates
with small acyl groups such as acetyl-
CoA (two carbons) and butyryl-CoA (four
carbons). M. tuberculosis FabH (MtFabH)
is unusual in that medium chain length
acyl groups of 14–20 carbons are pre-ferred substrates (Brown et al., 2005).
These acyl groups are produced by
a Type I fatty acid synthase (FAS) and
ultimately form the ‘‘tail’’ of the mycolic
acid (Barry et al., 1998). Initially, the acyl
tail is transferred from CoA to an active
site cysteine (C112) on MtFabH. MtFabH
then catalyzes the decarboxylative con-
densation of the acyl group with a second
substrate, malonyl-ACP. The product of
this reaction is further elongated by
a Type II FAS. Thus, MtFabH serves an
important role as a link between Type I
and Type II FASs in the production of
mycolic acids (Choi et al., 2000).
FabH enzymes bind CoA and ACP sub-
strates in a channel (the pantetheinate
channel) leading from the enzyme surface
to the active site cysteine residue. In
MtFabH, a second hydrophobic channel
(the acyl channel) leads from the active
site cysteine residue (C112) and forms
a cavity that is only accessible through the
pantetheinate channel. The crystal struc-
ture of MtFabH active site mutant C112A
was determined with bound lauroyl-CoA
substrate (Musayev et al., 2005). The sub-
strate was found in an ‘‘L’’-shaped confor-
mation with CoA occupying the pantethei-
nate channel and the 12 carbon lauroyl
moiety occupying the acyl channel. Based
on this structure, it appeared that the sub-
strate would have to thread all the way
through the pantetheinate channel to gain
access to the acyl channel.
Sachdeva et al. (2008) report new find-
ings that alter this perception of how
MtFabH binds substrates. Three inhibi-
tors of MtFabH are capable of covalent
attachment to the active site cysteine, ei-
ther by forming a thioester or a disulfide
linkage. Sachdeva and coworkers pres-
ent three crystal structures of MtFabH
with the bound inhibitors. In all three
cases, electron density attributable toChemistry & Biology 15, April 2008the covalently bound inhibitor is found in
the acyl channel, even though one of the
inhibitors contains a carboxylate group.
It is difficult to imagine this charged com-
pound threading through the hydrophobic
substrate binding channels to reach the
position observed in the crystal structure.
The most exciting observations, however,
involve a mutant MtFabH in which a small
residue lining the pantetheinate channel
was substituted with a bulky phenylala-
naine. This mutation, A246F, blocks the
pantetheinate channel, severing access
to the surface of the enzyme. Despite this
blockage, two crystal structures clearly
show covalently bound inhibitors occupy-
ing the acyl channel. As shown in Figure 1,
the A246F mutation would block the com-
pounds from reaching the active site in
a ‘‘substrate threading’’ model of binding.
However, if an ‘‘open state’’ is allowed,
the inhibitors can enter the active site and
covalently modify C112, as observed.
Based on their observations, Sachdeva
and coworkers propose a model in which
a concerted hinge motion exposes the
active site allowing acyl-CoA substrates
to easily access the acyl channel. A simi-
lar event may facilitate the release of
products. This model of substrate binding
builds on previous structural and bio-
chemical observations. In the absence of
ligands, E. coli FabH has been structurally
characterized in a partially disordered
state that appears to become more
ordered upon ligand binding (Qiu et al.,
2001). Similarly, modification of the active
site cysteine in one monomer of E. coli
FabH seems to reduce the reactivity of the
other monomer as if a structurally ordered
state was triggered, limiting access to the
active sites (Alhamadsheh et al., 2007).
Taken together, these results suggest
that substrates may bind to a pre-existing
open state of FabH without traversingª2008 Elsevier Ltd All rights reserved 309
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(A) The ‘‘substrate threading’’ model. Substrates must traverse through the pantetheinate channel to reach the acyl channel. The A246F mutation will block the
pantetheinate channel with a bulky phenylalanine side chain, preventing the substrate from reaching the active site.
(B) The ‘‘open state’’ model proposed by Sachdeva et al. (2008). Concerted conformational changes expose the channels and allow substrates to enter the
active site directly. The phenylalanine side chain of mutant A246F does not block the substrate (compound III is shown) from entering the active site and reacting
with C112.through the pantetheinate channel. Ulti-
mately, a more detailed understanding of
conformational changes in MtFabH will
aid in the discovery of novel therapeutics
to combat tuberculosis.
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